Reiff MI, Banez GA, Culbert TP. Children who have attentional disorders: diagnosis and evaluation. Pediatr Rev 1993; 14:455- 465.
Faraone SV, Sergeant J, Gillberg C, Biederman J. The worldwide prevalence of ADHD: is it an American condition? World Psychiatry 2003; 2:104-113.
Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007; 164:942-948. [CrossRef]
Connor DF, Barkley RA, Davis HT. A pilot study of methylphenidate, clonidine, or the combination in ADHD comorbid with aggressive oppositional defiant or conduct disorder. Clin Pediatr (Phila) 2000; 39:15-25. [CrossRef]
Weiss G. Attention Deficit Hyperactivity Disorder. Comprehensive Textbook of Child and Adolescent Psychiatry. Lewis M (editor). Second Ed. Williams & Wilkins Press, 1996; 544-563.
Challman TD, Lipsky JJ. Methylphenidate: its pharmacology and uses. Mayo Clin Proc 2000; 75:711-721. [CrossRef]
Morton WA, Stockton GG. Methylphenidate abuse and psychiatric side effects. Prim Care Companion J Clin Psychiatry 2000; 2:159-164. [CrossRef]
Bartlik B, Harmon G. Use of methylphenidate in a patient with glaucoma and attention-deficit hyperactivity disorder: a clinical dilemma. Arch Gen Psychiatry 1997; 54:188-189. [CrossRef]
Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 1999; 37:457-470. [CrossRef]
Yang P, Chung LC, Chen CS, Chen CC. Rapid improvement in academic grades following methylphenidate treatment in attention-deficit hyperactivity disorder. Psychiatry Clin Neurosci 2004; 58:37-41. [CrossRef]
Larranaga-Fragoso P, Noval S, Rivero JC, Boto-de-los- Bueis A. The effects of methylphenidate on refraction and anterior segment parameters in children with attention deficit hyperactivity disorder. J AAPOS 2015; 19:322-326. [CrossRef]
Lu CK, Kuang TM, Chou JC. Methylphenidate (Ritalin)- associated cataract and glaucoma. J Chin Med Assoc 2006; 69:589-590. [CrossRef]